More about chloroquine and hydroxychloroquine, CEBM (updated 27th June 2020)

Note added on 27 June: On 26 June the MHRA 2 External 0 0 0 announced false https://www.gov.uk/government/news/green-light-for-covid-19-trial-recruitment?utm_source=8a20f981-3745-403b-adff-3bdceb0147e4&utm_medium=email&utm_campaign=govuk-notifications&utm_content=weekly%E2%80%8B true false%> that it had “given the [COPCOV] clinical trial the green light to recruit more participants at the request of the COPCOV trialists, who are studying the use of hydroxychloroquine in preventing COVID-19. At the same time, the MHRA issued a 2 External 0 0 0 statement false https://www.gov.uk/governme nt/news/chloroquine-and-hydroxychloroquine-not-licensed-for-coronavirus-covid-19-treatment?utm_source=bb8e3c89-4107-4be7-90e2-126a118e38e8&utm_medium=email&utm_campaign=govuk-notifications&utm_content=weekly true false%> reminding prescribers that “Chloroquine and hydroxychloroquine are not licensed to treat COVID-19 related symptoms or prevent infection” and that “until we have clear, definitive evidence that these treatments are safe and effective for the treatment of COVID-19, they should only be used for this purpose within a clinic al trial.”​

Source: Current Awareness Service for Health (CASH) - June 29, 2020 Category: Consumer Health News Source Type: news